PL2965752T3 - Formulacja farmaceutyczna zawierająca ezetymib - Google Patents

Formulacja farmaceutyczna zawierająca ezetymib

Info

Publication number
PL2965752T3
PL2965752T3 PL15171262.7T PL15171262T PL2965752T3 PL 2965752 T3 PL2965752 T3 PL 2965752T3 PL 15171262 T PL15171262 T PL 15171262T PL 2965752 T3 PL2965752 T3 PL 2965752T3
Authority
PL
Poland
Prior art keywords
ezetimibe
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
PL15171262.7T
Other languages
English (en)
Inventor
Pasupuleti Giridhara Rao
Javed Hussain
Ganesh V. Gat
Original Assignee
Assia Chemical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40416944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2965752(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Assia Chemical Industries Ltd. filed Critical Assia Chemical Industries Ltd.
Publication of PL2965752T3 publication Critical patent/PL2965752T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
PL15171262.7T 2007-12-10 2008-12-09 Formulacja farmaceutyczna zawierająca ezetymib PL2965752T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2579DE2007 2007-12-10

Publications (1)

Publication Number Publication Date
PL2965752T3 true PL2965752T3 (pl) 2025-12-08

Family

ID=40416944

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15171262.7T PL2965752T3 (pl) 2007-12-10 2008-12-09 Formulacja farmaceutyczna zawierająca ezetymib

Country Status (8)

Country Link
US (1) US8858994B2 (pl)
EP (2) EP2965752B1 (pl)
CA (1) CA2708159C (pl)
EA (1) EA022269B1 (pl)
ES (2) ES2639995T3 (pl)
PL (1) PL2965752T3 (pl)
UA (1) UA103179C2 (pl)
WO (1) WO2009074286A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60045110D1 (de) 1999-12-01 2010-11-25 Univ Princeton Erungsmittel in organischen led's
EP2127641A1 (en) 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
EP2216016A1 (en) * 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
HUP1000327A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Composition containing nanostructured ezetibime and process for it's preparation
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
WO2013066279A1 (en) * 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
CN104173307A (zh) * 2014-08-29 2014-12-03 四川制药制剂有限公司 依折麦布片剂的制备方法
WO2016149191A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP3437636A1 (en) 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
CN111601590A (zh) * 2017-11-23 2020-08-28 浙江海正药业股份有限公司 一种海泽麦布片剂及其制备方法
WO2024041746A1 (en) * 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Fixed dose combination composition of obicetrapib and ezetimibe
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
WO2024042061A1 (en) * 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1995035277A1 (en) 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
EP1817280A1 (en) 2004-12-03 2007-08-15 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
US20070049748A1 (en) 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
CA2644905A1 (en) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
WO2008032338A2 (en) * 2006-09-11 2008-03-20 Manne Satyanarayana Reddy Improved process for the preparation of ezetimibe and its intermediates
WO2008089484A1 (en) 2007-01-20 2008-07-24 Dais Analytic Corporation Multi-phase selective mass transfer through a membrane
CN101679236B (zh) 2007-01-24 2013-03-06 克尔克公司 依泽替米贝的制备方法和其的衍生物
WO2008101723A2 (en) 2007-02-23 2008-08-28 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
CN101938995A (zh) * 2007-12-17 2011-01-05 克卡制药新梅斯托股份公司 包含非微粉化依泽替米贝微粒的悬浮液

Also Published As

Publication number Publication date
UA103179C2 (ru) 2013-09-25
WO2009074286A2 (en) 2009-06-18
CA2708159A1 (en) 2009-06-18
EP2965752A1 (en) 2016-01-13
ES2639995T3 (es) 2017-10-31
EA201000752A1 (ru) 2010-12-30
ES3040722T3 (en) 2025-11-04
WO2009074286A3 (en) 2009-07-30
EP2217214B1 (en) 2017-07-19
CA2708159C (en) 2016-01-26
US8858994B2 (en) 2014-10-14
EP2217214A2 (en) 2010-08-18
EP2965752B1 (en) 2025-09-03
EA022269B1 (ru) 2015-12-30
US20100291207A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
HUS1800043I1 (hu) 514 számú gyógyszerkészítmény
GB2450753B (en) New Pharmaceutical formulation
HUS1800007I1 (hu) Gyógyászati készítmény
PL2965752T3 (pl) Formulacja farmaceutyczna zawierająca ezetymib
GB0709031D0 (en) Pharmaceutical compounds
IL201366A0 (en) Pharmaceutical compounds
EP2133095A4 (en) PHARMACEUTICAL COMPOSITION
EP2133094A4 (en) PHARMACEUTICAL COMPOSITION
GB0721095D0 (en) Pharmaceutical compounds
GB0707087D0 (en) Pharmaceutical compounds
GB0725214D0 (en) Pharmaceutical compounds
GB0704932D0 (en) Pharmaceutical compounds
EP2224805A4 (en) PHARMACEUTICAL COMPOSITION
EP2224915A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0721669D0 (en) Pharmaceutical compounds
EP2224808A4 (en) PHARMACEUTICAL COMPOSITION
GB0614586D0 (en) Pharmaceutical Formulation
IL208788A (en) Pharmacy-based formulation
EP2275092A4 (en) PHARMACEUTICAL TAX FORMULATION
GB0705030D0 (en) Pharmaceutical formulation
IL195607A0 (en) Multiple unit pharmaceutical formulation
GB0805292D0 (en) Pharmaceutical formulation
GB0713093D0 (en) Pharmaceutical formulations
GB0711346D0 (en) Pharmaceutical compounds
GB0715675D0 (en) Pharmaceutical compounds